Bank of New York Mellon Corp lifted its holdings in LifeVantage Co. (NASDAQ:LFVN - Free Report) by 43.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 74,183 shares of the company's stock after purchasing an additional 22,620 shares during the period. Bank of New York Mellon Corp owned 0.59% of LifeVantage worth $1,300,000 as of its most recent filing with the SEC.
A number of other large investors also recently modified their holdings of the business. Barclays PLC increased its position in shares of LifeVantage by 38.2% during the third quarter. Barclays PLC now owns 41,966 shares of the company's stock valued at $507,000 after purchasing an additional 11,608 shares during the period. HighTower Advisors LLC bought a new position in shares of LifeVantage in the third quarter worth about $638,000. Ritholtz Wealth Management lifted its holdings in LifeVantage by 65.2% during the 4th quarter. Ritholtz Wealth Management now owns 47,348 shares of the company's stock worth $830,000 after buying an additional 18,682 shares in the last quarter. Finally, Copeland Capital Management LLC bought a new position in LifeVantage in the fourth quarter valued at about $65,000. 35.32% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several analysts have commented on the stock. Craig Hallum assumed coverage on shares of LifeVantage in a research report on Tuesday, January 14th. They set a "buy" rating and a $35.00 target price for the company. Lake Street Capital began coverage on LifeVantage in a research note on Thursday, December 19th. They issued a "buy" rating and a $26.00 price target on the stock.
Get Our Latest Stock Analysis on LifeVantage
Insider Transactions at LifeVantage
In other LifeVantage news, Director Raymond B. Greer sold 8,000 shares of LifeVantage stock in a transaction on Monday, February 10th. The stock was sold at an average price of $20.15, for a total value of $161,200.00. Following the completion of the transaction, the director now directly owns 99,288 shares of the company's stock, valued at $2,000,653.20. The trade was a 7.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 20.65% of the company's stock.
LifeVantage Price Performance
LFVN stock traded up $0.38 during mid-day trading on Thursday, reaching $15.03. The company had a trading volume of 124,581 shares, compared to its average volume of 115,965. The stock has a 50 day simple moving average of $18.95 and a two-hundred day simple moving average of $15.87. LifeVantage Co. has a 52 week low of $5.22 and a 52 week high of $27.38. The company has a market capitalization of $188.64 million, a price-to-earnings ratio of 26.84 and a beta of 0.74.
LifeVantage (NASDAQ:LFVN - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.08. LifeVantage had a return on equity of 34.29% and a net margin of 3.46%.
LifeVantage Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, March 17th. Stockholders of record on Monday, March 3rd were paid a dividend of $0.04 per share. The ex-dividend date was Monday, March 3rd. This represents a $0.16 dividend on an annualized basis and a dividend yield of 1.06%. LifeVantage's dividend payout ratio (DPR) is currently 28.57%.
About LifeVantage
(
Free Report)
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Further Reading

Before you consider LifeVantage, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeVantage wasn't on the list.
While LifeVantage currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.